GLPBio

DB2313

Catalog No.: GC62222Purity:>98.00%
COASDSData Sheet
DB2313 es un potente inhibidor del factor de transcripciÓn PU.1 con una apoptosis de 14 nM. DB2313 interrumpe la interacciÓn de PU.1 con los promotores de genes diana. DB2313 induce la apoptosis de las células de leucemia mieloide aguda (AML) y tiene efectos anticancerÍgenos.

Los productos son exclusivamente para uso en investigación. No aptos para uso humano. No vendemos a pacientes.

DB2313
Cas No.: 2170606-74-1
1mgIn Stock
$42.00
1
5 mgIn Stock
$42.00
1
10 mgIn Stock
$147.00
1
25 mgIn Stock
$235.00
1
50 mgIn Stock
$349.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citas (Citations)

Actualmente no hay citas disponibles para este producto. A continuación se muestran publicaciones seleccionadas que citan productos GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Descripción (Description)

DB2313 is a potent transcription factor PU.1 inhibitor with an IC50 of 14nM[1]. DB2313 disrupts the interaction of PU.1 with target gene promoters[2]. PU.1, a critical transcription factor in the hematopoietic system, plays key roles in myeloid and lymphoid cell differentiation, maintenance of hematopoietic stem cell functions, and the development of acute myeloid leukemia (AML)[3]. DB2313 is usually used in research related to AML and inflammation[4].

In vitro, DB2313 (10μg/ml; 72h) significantly inhibited the proliferation, migration, and invasion of GBM cells (U118MG and U87MG)[5].

In vivo, DB2313 (17mg/kg; every 2 days via intraperitoneal injection for 12 days) significantly suppressed tumor growth and enhanced the recruitment of CD4+ T helper 1 (Th1) and cytotoxic T/natural killer (NK) cells into tumors in the B16-OVA melanoma mouse model[6]. DB2313 (8mg/kg; intranasal administration; 5 days/week for 3 weeks) decreased airway mucus-secreting cell numbers and small airway collagen deposition, and significantly reduced airway hyperresponsiveness in a house dust mite (HDM)-induced experimental asthma mouse model[7].

References:
[1] Antony-Debre I, Paul A, Leite J, et al. Pharmacological inhibition of the transcription factor PU.1 in leukemia. J Clin Invest. 2017;127(12):4297-4313.
[2] Tu J, Chen W, Fang Y, et al. PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes. Ann Rheum Dis. 2023;82(2):198-211.
[3] Fisher RC, Scott EW. Role of PU.1 in hematopoiesis. Stem Cells. 1998;16(1):25-37.
[4] Tu X, Kim RY, Brown AC, et al. Airway and parenchymal transcriptomics in a novel model of asthma and COPD overlap. J Allergy Clin Immunol. 2022;150(4):817-829.e6.
[5] Zhang S, Zhao S, Qi Y, et al. SPI1-induced downregulation of FTO promotes GBM progression by regulating pri-miR-10a processing in an m6A-dependent manner. Mol Ther Nucleic Acids. 2022;27:699-717.
[6] Sleapnicov N, Ha SD, Zhong SJ, et al. Inhibition of the Transcription Factor PU.1 Suppresses Tumor Growth in Mice by Promoting the Recruitment of Cytotoxic Lymphocytes Through the CXCL9-CXCR3 Axis. Cancers (Basel). 2025;17(16):2684.
[7] Tu X, Gomez HM, Kim RY, et al. Airway and parenchyma transcriptomics in a house dust mite model of experimental asthma. Respir Res. 2023;24(1):32.

Protocolo (Protocol)

Cell experiment [1]:

Cell lines

glioma cell lines U87MG and U118MG

Preparation Method

The glioma cell lines U87MG and U118MG were cultured in DMEM containing 10% fetal bovine serum and 1% penicillin-streptomycin. All cells were maintained in a humidified incubator with 5% CO2 at 37℃. The cells were routinely tested for mycoplasma contamination. 2000 GBM cells were seeded in 96-well plates and measured cell viability using CCK-8 assay at 0, 24, 48, and 72h. GBM cells were treated with DMSO or DB2313 (10mg/mL). EdU assays were performed using an EdU assay kit with GBM cells seeded in well plates at 2×105 cells per well. 2×104 GBM cells were used for the Transwell assay. A total of 2×105 GBM cells were cultured in spheroid formation ECM for 72h to generate tumor spheroids and used for the 3D tumor spheroid invasion assay with a 96-well 3D spheroid BME cell invasion assay kit. Images were taken at 0, 24, 48, and 72h using microscope.

Reaction Conditions

10μg/ml; 72h

Applications

DB2313 significantly inhibited the proliferation, migration, and invasion of GBM cells (U118MG and U87MG).
Animal experiment [2]:

Animal models

Female wild-type BALB/c mice

Preparation Method

Female wild-type BALB/c mice were housed under specific pathogen-free conditions and maintained on a 12-hour day-night cycle with water and regular chow available ad libitum. Mice were treated intranasally with house dust mite (HDM; Dermatophagoides pteronyssinus) extract (25µg in 30µL PBS or saline (vehicle), 5 days per week for 3 weeks. One group of HDM-treated mice were treated with DB2313 (8mg/kg in PBS). Bronchoalveolar lavage fluid was collected. Mucus-secreting cells (MSCs) were stained and counted. Collagen was stained and analyzed. Airway hyperresponsiveness was assessed using the forced oscillation technique.

Dosage form

8mg/kg; intranasal administration; 5 days/week for 3 weeks

Applications

DB2313 decreased airway mucus-secreting cell numbers and small airway collagen deposition, and significantly reduced airway hyperresponsiveness in a house dust mite (HDM)-induced experimental asthma mouse model.

References:
[1] Zhang S, Zhao S, Qi Y, et al. SPI1-induced downregulation of FTO promotes GBM progression by regulating pri-miR-10a processing in an m6A-dependent manner. Mol Ther Nucleic Acids. 2022;27:699-717.
[2] Tu X, Gomez HM, Kim RY, et al. Airway and parenchyma transcriptomics in a house dust mite model of experimental asthma. Respir Res. 2023;24(1):32.

Documentos del producto (Product Documents)

Purity:>98.00%Appearance:A solid
COASDSData Sheet

Propiedades químicas (Chemical Properties)

N.º CAS
2170606-74-1
Fórmula molecular
C42H41FN8O2
Peso molecular
708.83
Solubilidad
DMSO : 3.7 mg/mL (5.22 mM; ultrasonic and warming and heat to 70°C)
Almacenamiento
Store at -20°C
Consejos generales
Seleccione un disolvente adecuado según los datos de solubilidad del producto. Una vez preparada, divida la solución madre en alícuotas para evitar ciclos repetidos de congelación y descongelación.
Utilice las soluciones madre en un plazo de 6 meses si se conservan a -80°C, o de 1 mes si se conservan a -20°C.
Para mejorar la solubilidad, caliente el tubo a 37°C y soníquelo durante un periodo adecuado.
Condiciones de envío
Las muestras de evaluación se envían con acumuladores de frío. Los demás tamaños se envían a temperatura ambiente o, previa solicitud, con acumuladores de frío.

Calculadoras (Calculators)Molaridad / Dilución / Peso molecular / Conversión de unidades / Formulación in vivo / Solubilidad

g/mol

Reviews

Review for DB2313

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%